Form 8-K
8-K — Silence Therapeutics plc
Accession: 0001193125-26-341240
Filed: 2026-08-10
Period: 2026-08-10
CIK: 0001479615
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — d162225d8k.htm (Primary)
EX-99.1 (d162225dex991.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d162225d8k.htm · Sequence: 1
8-K
00-0000000 0001479615 false true 0001479615 2026-08-10 2026-08-10 0001479615 dei:AdrMember 2026-08-10 2026-08-10 0001479615 us-gaap:CommonStockMember 2026-08-10 2026-08-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 10, 2026
Silence Therapeutics plc
(Exact name of Registrant as Specified in Its Charter)
England and Wales
001-39487
Not Applicable
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
12 Hammersmith Grove
London
United Kingdom
W6 7AP
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
American Depositary Shares, each representing three ordinary shares, nominal value £0.05 per share
SLN
The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.05 per share*
*
The Nasdaq Stock Market LLC
*
Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On August 10, 2026, Silence Therapeutics plc (the “Company”) issued a press release announcing its financial and business results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.
The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release dated August 10, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SILENCE THERAPEUTICS PLC
Date: August 10, 2026
By:
/s/ Iain Ross
Name: Iain Ross
Title: Interim Principal Executive Officer and Chairman of the Board of Directors
(Principal Executive Officer)
EX-99.1
EX-99.1
Filename: d162225dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
10 August 2026
LONDON, Silence Therapeutics plc, (Nasdaq:
SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026.
Business Highlights
Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders
•
Presented follow-up data from the Phase 1 SANRECO trial at the European
Hematology Association (EHA) 2026 Annual Congress in June 2026 demonstrating durable efficacy results and potential best-in-class profile for divesiran in PV. The EHA
2026 poster is available here.
•
Completed patient dosing in the Phase 2 SANRECO double-blind, placebo-controlled trial evaluating divesiran 6
mg/kg (Q6W and Q12W dosing intervals) in 48 phlebotomy-dependent PV patients in June 2026.
•
American Journal of Hematology published a preclinical study authored by Silence scientists exploring the
potential of TMPRSS6 silencing as a therapeutic approach for myelodysplastic syndrome (MDS) in June 2026. You can read the publication here.
SLN312 (AZD1705): Phase 1 siRNA silencing ANGPTL3 with a competitive profile for dyslipidemia
•
Phase 1 results generated under the Company’s AstraZeneca collaboration were presented by AstraZeneca
during a late-breaking oral presentation at the European Atherosclerosis Society (EAS) Congress in May. Results demonstrated a favorable safety profile and dose-dependent, durable reductions in ANGPTL3 protein levels as well as in atherogenic
lipoproteins including LDL-C, Apo-B and non-HDL-C. The EAS 2026 presentation is
available here.
Pre-clinical pipeline updates:
•
Generated additional preclinical data demonstrating the effect of SLN365 (GPR146) on lipids was reproduced
and not altered by co-treatment with statin or ezetimibe. The program is well positioned for a potential IND filing in 2027.
•
Generated additional preclinical data for SLN098 (INHBE) in a diet induced obesity mouse model
demonstrating reduced visceral fat and preservation of lean body mass. The program is well positioned for a potential IND filing in 2027.
Second Quarter 2026 Financial Results
•
Cash Position: Cash and cash equivalents were $72.1 million as of June 30, 2026.
•
R&D Expenses: Research and development (R&D) expenses were $9.1 million for the three
months ended June 30, 2026, compared to $17.6 million for the three months ended June 30, 2025. The $8.4 million decrease is mainly due to the zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel
costs.
•
G&A Expenses: General and administrative (G&A) expenses were $4.7 million for the three
months ended June 30, 2026, compared to $5.1 million for the three months ended June 30, 2025.
•
Net Loss: Net loss was $12.3 million, or $0.09 basic and diluted net loss per share for the
three months ended June 30, 2026, compared to a net loss of $27.4 million, or $0.19 basic and diluted net loss per share for the three months ended June 30, 2025.
•
Total outstanding shares were 141,739,180 ordinary shares (including shares in the form of American
Depositary Shares) as of June 30, 2026.
About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision
engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely
target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information,
please visit https://www.silence-therapeutics.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”
“plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These
forward-looking statements include, but are not limited to, statements about: the Company’s business strategy and plans, including the Company’s clinical development activities and timelines; the potential therapeutic benefits of the
Company’s product candidates; and the anticipated timing of initial topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain
necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates
either on its own or with potential partners; any undesirable side effects or other properties of the company’s product candidates; the Company’s reliance on third-party suppliers and manufacturers; the outcomes of any future
collaboration agreements; and the Company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors”
contained in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the Company’s other filings with the SEC. Any forward-looking
statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the Company undertakes no
obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Inquiries:
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
Tel: +1 (646) 637-3208
ir@silence-therapeutics.com
Silence Therapeutics plc
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share data)
Three months ended June 30,
Six months ended June 30,
2026
2025
2026
2025
Revenue
$
—
$
224
$
422
$
366
Cost of sales
—
(85
)
(11
)
(139
)
Gross profit
—
139
411
227
Research and development costs
(9,148
)
(17,647
)
(18,270
)
(38,460
)
General and administrative expenses
(4,717
)
(5,131
)
(11,743
)
(12,815
)
Restructuring charges
—
(1,324
)
—
(1,324
)
Operating loss
(13,865
)
(23,963
)
(29,602
)
(52,372
)
Foreign currency gain/(loss), net
151
(6,613
)
(331
)
(10,382
)
Other income, net
669
861
1,240
1,830
Benefit from R&D credit
778
2,371
1,469
5,050
Loss before income tax expense
(12,267
)
(27,344
)
(27,224
)
(55,874
)
Income tax expense
(1
)
(10
)
(1
)
(10
)
Net Loss
$
(12,268
)
$
(27,354
)
$
(27,225
)
$
(55,884
)
Loss per share (basic and diluted)
$
(0.09
)
$
(0.19
)
$
(0.19
)
$
(0.39
)
Weighted average shares outstanding (basic and diluted)
141,709,762
141,696,047
141,706,190
141,687,438
Silence Therapeutics plc
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share data)
June 30, 2026
December 31, 2025
Current assets
Cash and cash equivalents
$
72,054
$
11,277
Short-term investments
—
73,837
R&D benefit receivable
9,292
22,007
Other current assets
12,935
11,537
Total current assets
94,281
118,658
Property, plant and equipment
1,325
1,581
Operating lease
right-of-use assets
117
167
Goodwill
10,325
10,621
Other intangible assets
237
288
Other long-term assets
127
127
Total assets
$
106,412
$
131,442
Current liabilities
Contract liabilities
$
—
$
(168
)
Trade and other payables
(12,611
)
(13,356
)
Operating lease liabilities, current
(103
)
(89
)
Total current liabilities
(12,714
)
(13,613
)
Contract liabilities
(55,218
)
(55,454
)
Operating lease liabilities
(9
)
(71
)
Total liabilities
$
(67,941
)
$
(69,138
)
Commitments and contingencies
Shareholders’ equity
Ordinary shares - par value £0.05 per share; 141,739,180 shares
issued at June 30,
2026 (December 31, 2025: 141,701,848)
(10,292
)
(10,290
)
Additional paid-in capital
(621,152
)
(617,562
)
Accumulated deficit
589,632
562,572
Accumulated other comprehensive loss
3,341
2,976
Total shareholders’ equity
(38,471
)
(62,304
)
Total liabilities and shareholders’ equity
$
(106,412
)
$
(131,442
)
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Document and Entity Information
Aug. 10, 2026
Document And Entity Information [Line Items]
Document Type
8-K
Document Period End Date
Aug. 10, 2026
Entity Registrant Name
Silence Therapeutics plc
Entity Incorporation State Country Code
X0
Entity File Number
001-39487
Entity Tax Identification Number
00-0000000
Entity Address Address Line 1
12 Hammersmith Grove
Entity Address City Or Town
London
Entity Address Country
GB
Entity Address Postal Zip Code
W6 7AP
Country Region
44
City Area Code
20
Local Phone Number
3457 6900
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Entity Central Index Key
0001479615
Amendment Flag
false
ADR [Member]
Document And Entity Information [Line Items]
Security 12b Title
American Depositary Shares, each representing three ordinary shares, nominal value £0.05 per share
Trading Symbol
SLN
Security Exchange Name
NASDAQ
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title
Ordinary share, nominal value £0.05 per share
Security Exchange Name
NASDAQ
No Trading Symbol Flag
true
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Region code of country
+ References
No definition available.
+ Details
Name:
dei_CountryRegion
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true only for a security having no trading symbol.
+ References
No definition available.
+ Details
Name:
dei_NoTradingSymbolFlag
Namespace Prefix:
dei_
Data Type:
dei:trueItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- References
No definition available.
+ Details
Name:
sln_DocumentAndEntityInformationLineItems
Namespace Prefix:
sln_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=dei_AdrMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: